Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER4 | P35408 | 13/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.54 |
| ▸ | RECQL | P46063 | 1/20 | 0.54 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.54 |
| ▸ | F2RL3 | Q96RI0 | 1/20 | 0.53 |
| ▸ | ELANE | P08246 | 1/20 | 0.52 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17322917 | 0.91 | PTGER4 (0.60) | PTGER4SMN1; SMN2RECQLMAPK10F2RL3 | |
| SCHEMBL25969215 | 0.87 | PTGER4 (0.63) | PTGER4SMN1; SMN2RECQLMAPK10F2RL3 | |
| SCHEMBL25966960 | 0.84 | PTGER4 (0.72) | PTGER4 | |
| SCHEMBL28495961 | 0.84 | ELANE (0.49) | SMN1; SMN2RECQLMAPK10F2RL3ELANE | |
| SCHEMBL4480347 | 0.80 | F2RL3 (0.67) | PTGER4SMN1; SMN2RECQLMAPK10F2RL3 | |
| SCHEMBL12584561 | 0.79 | PTGER4 (0.63) | PTGER4 | |
| SCHEMBL25966954 | 0.78 | ELANE (0.65) | SMN1; SMN2F2RL3ELANECYP19A1TDP1 | |
| SCHEMBL6705844 | 0.77 | ELANE (0.50) | SMN1; SMN2RECQLMAPK10ELANELMNA | |
| SCHEMBL15880211 | 0.75 | PTGER4 (0.50) | PTGER4SMN1; SMN2RECQLMAPK10F2RL3 | |
| SCHEMBL3763723 | 0.75 | MAPK8 (0.55) | PTGER4MAPK10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230250088-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | NOVARTIS PHARMA AG (CH) | 2023-08-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230250088-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | STING1, CGAS, IRF3 | PTGER4 2573/4885SMN1; SMN2 2372/4885RECQL 165/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.